Literature DB >> 30921110

Neurocognition in treatment-resistant hypertension: profile and associations with cardiovascular biomarkers.

Patrick J Smith1, James A Blumenthal1, Alan L Hinderliter2, Stephanie M Mabe1, Jeanne E Schwartz1, Forgive Avorgbedor1, Andrew Sherwood1.   

Abstract

BACKGROUND: Hypertension in midlife has been associated with increased risk of stroke and neurocognitive decline. Few studies, however, have examined neurocognition among individuals with treatment-resistant hypertension or potential mechanisms by which treatment-resistant hypertension may impair neurocognition.
METHODS: We examined the pattern of neurocognitive impairment and potential mechanisms in a sample of 96 overweight adults with treatment-resistant hypertension, aged 41-81 years. Neurocognitive function was assessed using a 45-min test battery consisting of executive function and memory. Vascular and metabolic mechanisms examined included cerebrovascular risk factors (CVRFs: Framingham Stroke Risk Profile), insulin sensitivity (homeostatic model assessment of insulin resistance), waist-to-hip ratio, microvascular function (hyperemic response), and peak oxygen consumption from an exercise treadmill test. Simple path analyses were used to assess the association between potential vascular and metabolic mechanisms and neurocognition.
RESULTS: Neurocognitive impairments were common, with 70% of the sample exhibiting impaired performance on at least one executive function subtest and 38% on at least one measure of memory. Higher levels of aerobic fitness, greater insulin sensitivity, and better microvascular function, as well as lower CVRFs and waist-to-hip ratio were associated with better neurocognition. In path analyses, aerobic fitness, microvascular function, and CVRFs all were independently associated with neurocognitive performance. Insulin resistance associated with worse executive function but better memory performance among older participants.
CONCLUSION: Neurocognitive impairments are common in adults with treatment-resistant hypertension, particularly on tests of executive function. Better neurocognition is independently associated with aerobic fitness, microvascular function, and CVRFs.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30921110      PMCID: PMC7279118          DOI: 10.1097/HJH.0000000000002002

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  70 in total

1.  Revised Framingham Stroke Risk Profile to Reflect Temporal Trends.

Authors:  Carole Dufouil; Alexa Beiser; Leslie A McLure; Philip A Wolf; Christophe Tzourio; Virginia J Howard; Andrew J Westwood; Jayandra J Himali; Lisa Sullivan; Hugo J Aparicio; Margaret Kelly-Hayes; Karen Ritchie; Carlos S Kase; Aleksandra Pikula; Jose R Romero; Ralph B D'Agostino; Cécilia Samieri; Ramachandran S Vasan; Genevieve Chêne; George Howard; Sudha Seshadri
Journal:  Circulation       Date:  2017-02-03       Impact factor: 29.690

2.  Treatment and control of hypertension in the community: a prospective analysis.

Authors:  Donald M Lloyd-Jones; Jane C Evans; Martin G Larson; Daniel Levy
Journal:  Hypertension       Date:  2002-11       Impact factor: 10.190

3.  Insulin is differentially related to cognitive decline and atrophy in Alzheimer's disease and aging.

Authors:  Jeffrey M Burns; Robyn A Honea; Eric D Vidoni; Lewis J Hutfles; William M Brooks; Russell H Swerdlow
Journal:  Biochim Biophys Acta       Date:  2011-07-01

Review 4.  Physical exercise as a preventive or disease-modifying treatment of dementia and brain aging.

Authors:  J Eric Ahlskog; Yonas E Geda; Neill R Graff-Radford; Ronald C Petersen
Journal:  Mayo Clin Proc       Date:  2011-09       Impact factor: 7.616

5.  Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study.

Authors:  M F Elias; P K Elias; L M Sullivan; P A Wolf; R B D'Agostino
Journal:  Int J Obes Relat Metab Disord       Date:  2003-02

6.  Differences in the association of peripheral insulin and cognitive function in non-diabetic Alzheimer's disease cases and normal controls.

Authors:  Valory Pavlik; Paul Massman; Robert Barber; Rachelle Doody
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

7.  Midlife adiposity predicts earlier onset of Alzheimer's dementia, neuropathology and presymptomatic cerebral amyloid accumulation.

Authors:  Y-F Chuang; Y An; M Bilgel; D F Wong; J C Troncoso; R J O'Brien; J C Breitner; L Ferruci; S M Resnick; M Thambisetty
Journal:  Mol Psychiatry       Date:  2015-09-01       Impact factor: 15.992

8.  Left ventricular mass increase is associated with cognitive decline and dementia in the elderly independently of blood pressure.

Authors:  Angelo Scuteri; Roberta Coluccia; Lorenzo Castello; Edoardo Nevola; Anna Maria Brancati; Massimo Volpe
Journal:  Eur Heart J       Date:  2009-04-30       Impact factor: 29.983

9.  Risk factors for cognitive and functional change in one year in patients with Alzheimer's disease dementia from São Paulo, Brazil.

Authors:  Fabricio Ferreira de Oliveira; Glaucia Akiko Kamikado Pivi; Elizabeth Suchi Chen; Marilia Cardoso Smith; Paulo Henrique Ferreira Bertolucci
Journal:  J Neurol Sci       Date:  2015-10-30       Impact factor: 3.181

10.  Effects of exercise on brain activity during walking in older adults: a randomized controlled trial.

Authors:  Hiroyuki Shimada; Kenji Ishii; Hyuma Makizako; Kiichi Ishiwata; Keiichi Oda; Megumi Suzukawa
Journal:  J Neuroeng Rehabil       Date:  2017-05-30       Impact factor: 4.262

View more
  1 in total

1.  Lifestyle modification and cognitive function among individuals with resistant hypertension: cognitive outcomes from the TRIUMPH trial.

Authors:  Patrick J Smith; Andrew Sherwood; Alan L Hinderliter; Stephanie Mabe; Lana L Watkins; Linda Craighead; Krista Ingle; Crystal Tyson; Forgive Avorgbedor; Pao-Hwa Lin; William E Kraus; Lawrence Liao; James A Blumenthal
Journal:  J Hypertens       Date:  2022-06-10       Impact factor: 4.776

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.